Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024

Researchers also highlighted the significance of TTNT-D as a real-world measure of treatment efficacy, noting it provides insight into both clinical and patient-centered outcomes.

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Treatment with liso-cel induced long-term complete remission rates and high undetectable minimal residual disease rates in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma following progression on Bruton tyrosine kinase inhibition and venetoclax.

Ibrutinib remains a key treatment for relapsed chronic lymphocytic leukemia (CLL), but findings suggest that combining it with other therapies can improve response rates and may allow for treatment discontinuation in some patients.

Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, highlighting disparities in specialized cancer care.

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved progression-free survival in chronic lymphocytic leukemia (CLL) compared with standard chemoimmunotherapy.